Drug safety and tolerability in prophylactic migraine treatment

Bibliography

• Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629-808
   PubMed Web of Science ®Google Scholar
• RBLipton, WFStewart, SDiamond, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57
   PubMed Web of Science ®Google Scholar
• BKRasmussen, RJensen, MSchroll, JOlesen. Epidemiology of headache in a general population – a prevalence study. J Clin Epidemiol 1991;44:1147-57
   PubMed Web of Science ®Google Scholar
• TASmitherman, RBurch, HSheikh, ELoder. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache 2013;53:427-36
   PubMed Web of Science ®Google Scholar
• TJSteiner, GGururaj, CAndree, et al. Diagnosis, prevalence estimation and burden measurement in population surveys of headache: presenting the HARDSHIP questionnaire. J Headache Pain 2014;15:3
   PubMed Web of Science ®Google Scholar
• TVos, ADFlaxman, MNaghavi, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-96
   PubMed Web of Science ®Google Scholar
• PCTfelt-Hansen, TPihl, AHougaard, DDMitsikostas. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. Expert Opin Investig Drugs 2014;23:375-85
   PubMed Web of Science ®Google Scholar
• LJLauner, GMTerwindt, MDFerrari. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999;53:537-42
   PubMed Web of Science ®Google Scholar
• WEWaters. Community studies of the prevalence of headache. Headache 1970;9:178-86
   PubMedGoogle Scholar
• JTajti, APardutz, EVamos, et al. Migraine is a neuronal disease. J Neural Transm 2011;118:511-24
   PubMed Web of Science ®Google Scholar
• LVecsei, LSzalardy, FFulop, JToldi. Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov 2013;12:64-82
   PubMed Web of Science ®Google Scholar
• LVecsei, BTuka, JTajti. Role of PACAP in migraine headaches. Brain 2014;137:650-1
   PubMed Web of Science ®Google Scholar
• FAndrasik, GLLipchik, DCMcCrory, DAWittrock. Outcome measurement in behavioral headache research: headache parameters and psychosocial outcomes. Headache 2005;45:429-37
   PubMed Web of Science ®Google Scholar
• SEvers. Treatment of migraine with prophylactic drugs. Expert Opin Pharmacother 2008;9:2565-73
   PubMed Web of Science ®Google Scholar
• SEvers, JAfra, AFrese, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol 2009;16:968-81
   PubMed Web of Science ®Google Scholar
• SDSilberstein, SHolland, FFreitag, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-45
   PubMed Web of Science ®Google Scholar
• ESKristoffersen, CLundqvist. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf 2014;5:87-99
   PubMedGoogle Scholar
• RBLipton, DSerrano, RANicholson, et al. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2013;53:1548-63
   PubMed Web of Science ®Google Scholar
• RBLipton, MEBigal, MDiamond, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9
   PubMed Web of Science ®Google Scholar
• SHolland, SDSilberstein, FFreitag, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1346-53
   PubMed Web of Science ®Google Scholar
• JYChung, MWKim, MKim. Efficacy of zonisamide in migraineurs with nonresponse to topiramate. Biomed Res Int 2014;2014:891348
   PubMed Web of Science ®Google Scholar
• YIJion, ARaff, BMGrosberg, RWEvans. The risk and management of kidney stones from the use of topiramate and zonisamide in migraine and idiopathic intracranial hypertension. Headache 2015;55:161-6
   PubMed Web of Science ®Google Scholar
• HGMarkley. Verapamil and migraine prophylaxis: mechanisms and efficacy. Am J Med 1991;90:48S-53S
   PubMed Web of Science ®Google Scholar
• HOkuma, KIijima, TYasuda, et al. Preventive effect of cyproheptadine hydrochloride in refractory patients with frequent migraine. Springerplus 2013;2:573
   PubMedGoogle Scholar
• VPizza, VBusillo, AAgresta, et al. Elderly patients with migraine: an open-label study on prophylaxis therapy with levetiracetam. Cent Nerv Syst Agents Med Chem 2011;11:31-4
   PubMedGoogle Scholar
• TPringsheim, WDavenport, GMackie, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 2012;39:S1-59
   PubMed Web of Science ®Google Scholar
• AVerma, DSrivastava, AKumar, VSingh. Levetiracetam in migraine prophylaxis: a randomized placebo-controlled study in a rural medical institute in northern India. Clin Neuropharmacol 2013;36:193-7
   PubMed Web of Science ®Google Scholar
• MLinde, WMMulleners, EPChronicle, DCMcCrory. Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010608
   PubMed Web of Science ®Google Scholar
• VLimmroth, MCMichel. The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001;52:237-43
   PubMed Web of Science ®Google Scholar
• KGShields, PJGoadsby. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain 2005;128:86-97
   PubMed Web of Science ®Google Scholar
• CAyata, HJin, CKudo, et al. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol 2006;59:652-61
   PubMed Web of Science ®Google Scholar
• DPNicholls, DWHarron, JMcAinsh, et al. Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers. Br J Clin Pharmacol 1982;14:727-32
   PubMed Web of Science ®Google Scholar
• YMasubuchi, SHosokawa, THorie, et al. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispos 1994;22:909-15
   PubMed Web of Science ®Google Scholar
• CMCastleden, CFGeorge. The effect of ageing on the hepatic clearance of propranolol. Br J Clin Pharmacol 1979;7:49-54
   PubMed Web of Science ®Google Scholar
• TEWideroe, TVigander. Propranolol in the treatment of migraine. Br Med J 1974;2:699-701
   PubMed Web of Science ®Google Scholar
• PTfelt-Hansen, BStandnes, PKangasneimi, et al. Timolol vs propranolol vs placebo in common migraine prophylaxis: a double-blind multicenter trial. Acta Neurol Scand 1984;69:1-8
   PubMed Web of Science ®Google Scholar
• APradalier, GSerratrice, MCollard, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia 1989;9:247-53
   PubMed Web of Science ®Google Scholar
• TAShamliyan, JYChoi, RRamakrishnan, et al. Preventive pharmacologic treatments for episodic migraine in adults. J Gen Intern Med 2013;28:1225-37
   PubMed Web of Science ®Google Scholar
• RShiri, JKoskimaki, JHakkinen, et al. Cardiovascular drug use and the incidence of erectile dysfunction. Int J Impot Res 2007;19:208-12
   PubMed Web of Science ®Google Scholar
• JBKostis, RCRosen, BCHolzer, et al. CNS side effects of centrally-active antihypertensive agents: a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males. Psychopharmacology (Berl) 1990;102:163-70
   PubMed Web of Science ®Google Scholar
• RFogari, AZoppi. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging 2004;21:377-93
   PubMed Web of Science ®Google Scholar
• RCRosen, JBKostis, AWJekelis. Beta-blocker effects on sexual function in normal males. Arch Sex Behav 1988;17:241-55
   PubMed Web of Science ®Google Scholar
• PKangasniemi, CHedman. Metoprolol and propranolol in the prophylactic treatment of classical and common migraine. A double-blind study. Cephalalgia 1984;4:91-6
   PubMed Web of Science ®Google Scholar
• BSRao, DGDas, VRTaraknath, YSarma. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India 2000;48:223-6
   PubMed Web of Science ®Google Scholar
• AKScott, TWalley, AMBreckenridge, et al. Lack of an interaction between propranolol and sumatriptan. Br J Clin Pharmacol 1991;32:581-4
   PubMed Web of Science ®Google Scholar
• MRGoldberg, DSciberras, MDe Smet, et al. Influence of beta-adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5-HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. Br J Clin Pharmacol 2001;52:69-76
   PubMed Web of Science ®Google Scholar
• RWPeck, EJSeaber, RDixon, et al. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Br J Clin Pharmacol 1997;44:595-9
   PubMed Web of Science ®Google Scholar
• HCDiener, VLimmroth. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001;10:1831-45
   PubMed Web of Science ®Google Scholar
• DTKo, PRHebert, CSCoffey, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002;288:351-7
   PubMed Web of Science ®Google Scholar
• EJPerez-Stable, TJCoates, RBBaron, et al. Comparison of a lifestyle modification program with propranolol use in the management of diastolic hypertension. J Gen Intern Med 1995;10:419-28
   PubMed Web of Science ®Google Scholar
• FRTaylor. Weight change associated with the use of migraine-preventive medications. Clin Ther 2008;30:1069-80
   PubMed Web of Science ®Google Scholar
• JVerspeelt, PDe Locht, WKAmery. Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. Cephalalgia 1996;16:328-36; discussion 288
   PubMed Web of Science ®Google Scholar
• KLinde, KRossnagel. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004;CD003225
   PubMedGoogle Scholar
• HSpahn, WKirch, EMutschler, et al. Pharmacokinetic and pharmacodynamic interactions between phenprocoumon and atenolol or metoprolol. Br J Clin Pharmacol 1984;17(Suppl 1):97S-102S
   PubMedGoogle Scholar
• CMBlake, EDKharasch, MSchwab, PNagele. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther 2013;94:394-9
   PubMed Web of Science ®Google Scholar
• TJSteiner, RJoseph, CHedman, FCRose. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. Headache 1988;28:15-23
   PubMed Web of Science ®Google Scholar
• MSiniatchkin, FAndrasik, PKropp, et al. Central mechanisms of controlled-release metoprolol in migraine: a double-blind, placebo-controlled study. Cephalalgia 2007;27:1024-32
   PubMed Web of Science ®Google Scholar
• PSSorensen, BHLarsen, MJRasmussen, et al. Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache 1991;31:650-7
   PubMed Web of Science ®Google Scholar
• HCDiener, EHartung, JChrubasik, et al. A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomized, controlled, double-blind, parallel group phase III study. Cephalalgia 2001;21:120-8
   PubMed Web of Science ®Google Scholar
• AFSmelt, WJAssendelft, CEvan Dijk, JWBlom. Triptan use after starting prophylactic migraine treatment: a retrospective cohort study in a primary care population. Cephalalgia 2014;34:927-32
   PubMed Web of Science ®Google Scholar
• CPQuarterman, MJKendall, DBJack. The effect of age on the pharmacokinetics of metoprolol and its metabolites. Br J Clin Pharmacol 1981;11:287-94
   PubMed Web of Science ®Google Scholar
• AAgnoli. The classification of calcium antagonists by the WHO expert committee: relevance in neurology. Cephalalgia 1988;8(Suppl 8):7-10
   PubMedGoogle Scholar
• OEDella Paschoa, AHoogerkamp, PMEdelbroek, et al. Pharmacokinetic-pharmacodynamic correlation of lamotrigine, flunarizine, loreclezole, CGP40116 and CGP39551 in the cortical stimulation model. Epilepsy Res 2000;40:41-52
   PubMed Web of Science ®Google Scholar
• BHolmes, RNBrogden, RCHeel, et al. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984;27:6-44
   PubMed Web of Science ®Google Scholar
• PLouis. A double-blind placebo-controlled prophylactic study of flunarizine (Sibelium) in migraine. Headache 1981;21:235-9
   PubMed Web of Science ®Google Scholar
• GMentenopoulos, TManafi, JLogothetis, SBostantzopoulou. Flunarizine in the prevention of classical migraine: a placebo-controlled evaluation. Cephalalgia 1985;5(Suppl 2):135-40
   PubMedGoogle Scholar
• HCDiener, JMatias-Guiu, EHartung, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 2002;22:209-21
   PubMed Web of Science ®Google Scholar
• CHLucking, WOestreich, RSchmidt, DSoyka. Flunarizine vs. propranolol in the prophylaxis of migraine: two double-blind comparative studies in more than 400 patients. Cephalalgia 1988;8(Suppl 8):21-6
   PubMedGoogle Scholar
• NLuo, WDi, AZhang, et al. A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Med 2012;13:80-6
   PubMed Web of Science ®Google Scholar
• MSBerilgen, SBulut, MGonen, et al. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005;25:1048-53
   PubMed Web of Science ®Google Scholar
• GHde Bock, JEelhart, HWvan Marwijk, et al. A postmarketing study of flunarizine in migraine and vertigo. Pharm World Sci 1997;19:269-74
   PubMed Web of Science ®Google Scholar
• JVerspeelt, PDe Locht, WKAmery. Postmarketing study of the use of flunarizine in vestibular vertigo and in migraine. Eur J Clin Pharmacol 1996;51:15-22
   PubMed Web of Science ®Google Scholar
• JHoffmann, SAkerman, PJGoadsby. Efficacy and mechanism of anticonvulsant drugs in migraine. Expert Rev Clin Pharmacol 2014;7:191-201
   PubMed Web of Science ®Google Scholar
• LCChen, MHChou, MFLin, LLYang. Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers. J Clin Pharm Ther 2000;25:453-9
   PubMed Web of Science ®Google Scholar
• MLinde, WMMulleners, EPChronicle, DCMcCrory. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010611
   PubMed Web of Science ®Google Scholar
• NTMathew, JRSaper, SDSilberstein, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-6
   PubMed Web of Science ®Google Scholar
• JKlapper. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17:103-8
   PubMed Web of Science ®Google Scholar
• RShahien, KBeiruti. Preventive agents for migraine: focus on the antiepileptic drugs. J Cent Nerv Syst Dis 2012;4:37-49
   PubMedGoogle Scholar
• FGFreitag, SDCollins, HACarlson, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652-9
   PubMed Web of Science ®Google Scholar
• WMMulleners, DCMcCrory, MLinde. Antiepileptics in migraine prophylaxis: an updated Cochrane review. Cephalalgia 2015;35:51-62
   PubMed Web of Science ®Google Scholar
• AMBlumenfeld, JDSchim, TJChippendale. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008;48:210-20
   PubMed Web of Science ®Google Scholar
• AVKrymchantowski, CCJevoux. Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective “real-world” study. Headache 2011;51:554-8
   PubMed Web of Science ®Google Scholar
• PPerucca, FGGilliam. Adverse effects of antiepileptic drugs. Lancet Neurol 2012;11:792-802
   PubMed Web of Science ®Google Scholar
• PJGoadsby, TSprenger. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol 2010;9:285-98
   PubMed Web of Science ®Google Scholar
• MJMarmura. Safety of topiramate for treating migraines. Expert Opin Drug Saf 2014;13:1241-7
   PubMed Web of Science ®Google Scholar
• MBialer, TShekh-Ahmad, TLBraun, MBHalvorsen. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. Epilepsia 2013;54:1444-52
   PubMed Web of Science ®Google Scholar
• SDSilberstein, EBen-Menachem, RPShank, FWiegand. Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther 2005;27:154-65
   PubMed Web of Science ®Google Scholar
• JLBrandes, JRSaper, MDiamond, et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-73
   PubMed Web of Science ®Google Scholar
• JRStorey, CSCalder, DEHart, DLPotter. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41:968-75
   PubMed Web of Science ®Google Scholar
• FAshtari, VShaygannejad, MAkbari. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 2008;118:301-5
   PubMed Web of Science ®Google Scholar
• DAfshari, SRafizadeh, MRezaei. A comparative study of the effects of low-dose topiramate versus sodium valproate in migraine prophylaxis. Int J Neurosci 2012;122:60-8
   PubMed Web of Science ®Google Scholar
• MLinde, WMMulleners, EPChronicle, DCMcCrory. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev 2013;6:CD010610
   PubMed Web of Science ®Google Scholar
• SEvers, RJensen; European Federation of Neurological Societies. Treatment of medication overuse headache – guideline of the EFNS headache panel. Eur J Neurol 2011;18:1115-21
   PubMed Web of Science ®Google Scholar
• MBRussell, CLundqvist. Prevention and management of medication overuse headache. Curr Opin Neurol 2012;25:290-5
   PubMed Web of Science ®Google Scholar
• LEdvinsson, MLinde. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet 2010;376:645-55
   PubMed Web of Science ®Google Scholar
• SForderreuther, MMayer, AStraube. Treatment of cluster headache with topiramate: effects and side-effects in five patients. Cephalalgia 2002;22:186-9
   PubMed Web of Science ®Google Scholar
• NFritz, SGlogau, JHoffmann, et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005;6:373-81
   PubMed Web of Science ®Google Scholar
• IGarza, JWSwanson. Prophylaxis of migraine. Neuropsychiatr Dis Treat 2006;2:281-91
   PubMedGoogle Scholar
• JLuykx, MMason, MDFerrari, JCarpay. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther 2009;85:283-8
   PubMed Web of Science ®Google Scholar
• MEtminan, DMaberley, FSMikelberg. Use of topiramate and risk of glaucoma: a case-control study. Am J Ophthalmol 2012;153:827-30
   PubMed Web of Science ®Google Scholar
• JDHo, JJKeller, CYTsai, et al. Topiramate use and the risk of glaucoma development: a population-based follow-up study. Am J Ophthalmol 2013;155:336-41.e1
   PubMed Web of Science ®Google Scholar
• SKGupta, JCShah, SSHwang. Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. Br J Clin Pharmacol 1999;48:71-8
   PubMed Web of Science ®Google Scholar
• PDharmshaktu, VTayal, BSKalra. Efficacy of antidepressants as analgesics: a review. J Clin Pharmacol 2012;52:6-17
   PubMed Web of Science ®Google Scholar
• SDSilberstein, PJGoadsby. Migraine: preventive treatment. Cephalalgia 2002;22:491-512
   PubMed Web of Science ®Google Scholar
• ERichelson. Tricyclic antidepressants and histamine H1 receptors. Mayo Clin Proc 1979;54:669-74
   PubMed Web of Science ®Google Scholar
• SHSnyder, HIYamamura. Antidepressants and the muscarinic acetylcholine receptor. Arch Gen Psychiatry 1977;34:236-9
   PubMed Web of Science ®Google Scholar
• JRCouch; Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011;51:33-51
   PubMed Web of Science ®Google Scholar
• JRCouch, RSHassanein. Amitriptyline in migraine prophylaxis. Arch Neurol 1979;36:695-9
   PubMed Web of Science ®Google Scholar
• DKZiegler, AHurwitz, SPreskorn, et al. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. Arch Neurol 1993;50:825-30
   PubMed Web of Science ®Google Scholar
• DWDodick, FFreitag, JBanks, et al. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther 2009;31:542-59
   PubMed Web of Science ®Google Scholar
• MGore, EDukes, DRowbotham, et al. Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline. Pain Pract 2006;6:265-72
   PubMedGoogle Scholar
• RBLipton, HGobel, KMEinhaupl, et al. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology 2004;63:2240-4
   PubMed Web of Science ®Google Scholar
• NAnderson, TMeier, JBorlak. Toxicogenomics applied to cultures of human hepatocytes enabled an identification of novel petasites hybridus extracts for the treatment of migraine with improved hepatobiliary safety. Toxicol Sci 2009;112:507-20
   PubMed Web of Science ®Google Scholar
• EFacco, ALiguori, FPetti, et al. Acupuncture versus valproic acid in the prophylaxis of migraine without aura: a prospective controlled study. Minerva Anestesiol 2013;79:634-42
   PubMed Web of Science ®Google Scholar
• JHesse, BMogelvang, HSimonsen. Acupuncture versus metoprolol in migraine prophylaxis: a randomized trial of trigger point inactivation. J Intern Med 1994;235:451-6
   PubMed Web of Science ®Google Scholar
• KLinde, GAllais, BBrinkhaus, et al. Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev 2009;CD001218
   PubMed Web of Science ®Google Scholar
• SKAurora, DWDodick, HCDiener, et al. OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand 2014;129:61-70
   PubMed Web of Science ®Google Scholar
• JTajti, DSzok, BTuka, et al. [Botulinum neurotoxin – a therapy in migraine]. Ideggyogy Sz 2012;65:77-82
   PubMedGoogle Scholar
• PLiberini, EPari, SGazzina, et al. Technique of injection of onabotulinumtoxin A for chronic migraine: the PREEMPT injection paradigm. Neurol Sci 2014;35(Suppl 1):41-3
   PubMedGoogle Scholar
• ECernuda-Morollon, CRamon, DLarrosa, et al. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year? Cephalalgia 2014. [Epub ahead of print]
   Google Scholar
• DWDodick, CCTurkel, REDeGryse, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921-36
   PubMed Web of Science ®Google Scholar
• NTMathew, SFJaffri. A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 2009;49:1466-78
   PubMed Web of Science ®Google Scholar
• YHu, XGuan, LFan, LJin. Triptans in prevention of menstrual migraine: a systematic review with meta-analysis. J Headache Pain 2013;14:7
   PubMed Web of Science ®Google Scholar
• MSanford. Frovatriptan: a review of its use in the acute treatment of migraine. CNS Drugs 2012;26:791-811
   PubMed Web of Science ®Google Scholar
• LSavi, SMogavero, CGEgan. Efficacy and pharmacokinetic activity of frovatriptan compared to rizatriptan in patients with moderate-to-severe migraine. Drug Des Devel Ther 2014;8:983-92
   PubMed Web of Science ®Google Scholar
• SJTepper, DMillson. Safety profile of the triptans. Expert Opin Drug Saf 2003;2:123-32
   PubMedGoogle Scholar
• SDSilberstein, AHElkind, CSchreiber, CKeywood. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 2004;63:261-9
   PubMed Web of Science ®Google Scholar
• JLBrandes, APoole, MKallela, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009;29:1133-48
   PubMed Web of Science ®Google Scholar
• AWFox, MLDiamond, ELSpierings. Migraine during pregnancy: options for therapy. CNS Drugs 2005;19:465-81
   PubMed Web of Science ®Google Scholar
• MCassina, EDi Gianantonio, IToldo, et al. Migraine therapy during pregnancy and lactation. Expert Opin Drug Saf 2010;9:937-48
   PubMed Web of Science ®Google Scholar
• RDavanzo, JBua, GPaloni, GFacchina. Breastfeeding and migraine drugs. Eur J Clin Pharmacol 2014;70:1313-24
   PubMed Web of Science ®Google Scholar
• SHutchinson, MJMarmura, ACalhoun, et al. Use of common migraine treatments in breast-feeding women: a summary of recommendations. Headache 2013;53:614-27
   PubMed Web of Science ®Google Scholar
• NTMathew. Antiepileptic drugs in migraine prevention. Headache 2001;41(Suppl 1):S18-24
   PubMedGoogle Scholar
• LLMueller. Diagnosing and managing migraine headache. J Am Osteopath Assoc 2007;107:ES10-16
   PubMedGoogle Scholar
• LHood, MFlores. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol 2012;29:613-24
   PubMed Web of Science ®Google Scholar
• ZHepp, LMBloudek, SFVaron. Systematic review of migraine prophylaxis adherence and persistence. J Manag Care Pharm 2014;20:22-33
   PubMed Web of Science ®Google Scholar
• MEBigal, SWalter. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs 2014;28:389-99
   PubMed Web of Science ®Google Scholar